Results 191 to 200 of about 40,704 (273)

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy

Clinical pharmacology and therapy, 2017
Brad Moriyama, A. Obeng, A. Obeng, Julia M. Barbarino, S. Penzak, Stacey A. Henning, Stuart A. Scott, J. A. Agúndez, J. Wingard, Howard L. McLeod, Teri E. Klein, S. J. Cross, K. Caudle, Thomas J. Walsh   +13 more
semanticscholar   +1 more source

The types and durations of antiplatelet drugs for symptomatic vertebrobasilar artery stenosis: a retrospective study. [PDF]

Front Neurol
Liu X, Zhong G, Gu H, Wen Y, Zhong X, Zhang J, Xie Y.   +6 more
europepmc   +1 more source

Molecular Ancestry Across Allelic Variants of <i>SLC22A1</i>, <i>SLC22A2</i>, <i>SLC22A3</i>, <i>ABCB1</i>, <i>CYP2C8</i>, <i>CYP2C9</i>, and <i>CYP2C19</i> in Mexican-Mestizo DMT2 Patients. [PDF]

Biomedicines
Ortega-Ayala A, de la Cruz CG, Dorado P, Rodrigues-Soares F, Castillo-Nájera F, LLerena A, Molina-Guarneros J.   +6 more
europepmc   +1 more source

Prevalence of Actionable Exposures to Pharmacogenetic Medications Among Solid Organ Transplant Recipients in a Population-Scale Biobank. [PDF]

J Pers Med
Radwan A, Deininger KM, Ambardekar AV, Anderson HD, Rafaels N, Saba LM, The Colorado Center For Personalized Medicine, Aquilante CL.   +7 more
europepmc   +1 more source

Frequency and Implications of High-Risk Pharmacogenomic Phenotypes Identified in a Diverse Australian Pediatric Oncology Cohort. [PDF]

Clin Transl Sci
Moore C, Halman A, Stenta T, Khatri D, Williams E, Dyas R, Stolper J, Elliott DA, Conyers R.   +8 more
europepmc   +1 more source

Polypharmacy and pharmacogenomics in high-acuity behavioral health care for autism spectrum disorder: a retrospective study. [PDF]

Child Adolesc Psychiatry Ment Health
Garrison SR, Schweinert SA, Boyer MW, Singh M, Vadapalli S, Engelmann JM, Schwartz RA, Hartig MM.   +7 more
europepmc   +1 more source

Drug Interactions With Tamoxifen and Treatment Effectiveness in Premenopausal Breast Cancer Patients: A Bayesian Joint Modeling Approach. [PDF]

Pharmacoepidemiol Drug Saf
Woolpert KM, Cronin-Fenton DP, Damkier P, Kjærsgaard A, Hamilton-Dutoit S, Ejlertsen B, MacLehose RF, Christiansen P, Silliman RA, Lash TL, Ahern TP, Collin LJ.   +11 more
europepmc   +1 more source

CYP2C19 Loss-of-Function is an Associated Risk Factor for Premature Coronary Artery Disease: A Case–Control Study

International Journal of General Medicine
Wenhao Chen,1 Yuanliang Liu,2 Xunwei Deng,3 Bin Li,1 Hao Wang,1 Guoliang Wei,1 Kehui Chen,1 Shen Wang1 1Center for Cardiovascular Diseases, Meizhou People’s Hospital, Meizhou, People’s Republic of China; 2Department of Computer Tomography, Meizhou People’
Chen W, Liu Y, Deng X, Li B, Wang H, Wei G, Chen K, Wang S   +7 more
doaj  

Protocol for an observational study to assess the impact of pharmacogenetics on outcomes in vascular surgery (PROSPER). [PDF]

BMJ Open
Burke KA, Mirza S, Wright S, Greaves NS, Newman WG, McDermott JH.   +5 more
europepmc   +1 more source

Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype‐Guided Antiplatelet Therapy

Clinical pharmacology and therapy, 2018
P. Empey, J. Stevenson, S. Tuteja, K. Weitzel, D. Angiolillo, A. Beitelshees, James C. Coons, Julio D. Duarte, Francesco Franchi, L. Jeng, Julie A. Johnson, R. Kreutz, N. Limdi, Kristin A. Maloney, Aniwaa Owusu Obeng, J. Peterson, Natasha J. Petry, V. Pratt, F. Rollini, S. Scott, T. Skaar, M. Vesely, G. Stouffer, R. Wilke, L. Cavallari, Craig R. Lee   +25 more
semanticscholar   +1 more source